KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Non-Current Deferred Tax Liability (2016 - 2026)

Bio-Rad Laboratories has reported Non-Current Deferred Tax Liability over the past 18 years, most recently at $881.8 million for Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability rose 4.88% to $881.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $881.8 million through Mar 2026, up 4.88% year-over-year, with the annual reading at $1.1 billion for FY2025, 14.26% up from the prior year.
  • Non-Current Deferred Tax Liability was $881.8 million for Q1 2026 at Bio-Rad Laboratories, down from $1.1 billion in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $2.0 billion in Q1 2022 and troughed at $840.8 million in Q1 2025.
  • The 5-year median for Non-Current Deferred Tax Liability is $1.4 billion (2023), against an average of $1.3 billion.
  • Year-over-year, Non-Current Deferred Tax Liability crashed 58.41% in 2022 and then increased 14.26% in 2025.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $1.8 billion in 2022, then decreased by 7.16% to $1.6 billion in 2023, then tumbled by 43.59% to $927.2 million in 2024, then increased by 14.26% to $1.1 billion in 2025, then fell by 16.76% to $881.8 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Non-Current Deferred Tax Liability are $881.8 million (Q1 2026), $1.1 billion (Q4 2025), and $872.6 million (Q3 2025).